Risk management of adverse effects of antimalarial drugs: Knowledge of Physicians and Pharmacists in KAYES, MALI

Boubacar Traore; Gladys Tsoumbou Bakana; Alassane Aboubacar Oumar

doi:10.1051/e3sconf/202131901050

All issues

Volume 319 (2021)

E3S Web Conf., 319 (2021) 01050

References

Open Access

Issue		E3S Web Conf. Volume 319, 2021 International Congress on Health Vigilance (VIGISAN 2021)


Article Number		01050
Number of page(s)		7
DOI		https://doi.org/10.1051/e3sconf/202131901050
Published online		09 November 2021

World Health Organization & Global Malaria Programme. Global technical strategy for malaria, 2016-2030. (2015). [Google Scholar]
World Health Organization. World malaria report 2020. (2021). [Google Scholar]
Fougere, É. & Buxeraud, J. Les médicaments antipaludiques. Actual. Pharm. 57, 30–35 2018. [Google Scholar]
Organisation Mondiale de la Santé. La prise en charge du paludisme grave : Guide Pratique. (2013). [Google Scholar]
World Health Organization. Guidelines for the treatment of malaria. (2015). [Google Scholar]
Assefa, D. G. et al. Efficacy and safety of dihydroartemisinin-piperaquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Ugandan children: a systematic review and meta-analysis of randomized control trials. Malar. J. 20, 174 (2021). [Google Scholar]
Nji, A. M. et al. Randomized non-inferiority and safety trial of dihydroartemisin-piperaquine and artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroonian children. Malar. J. 14, 27 (2015). [Google Scholar]
Ndiaye, J. L. et al. Randomized, multicentre assessment of the efficacy and safety of ASAQ--a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria. Malar. J. 8, 125 (2009). [Google Scholar]
Ndiaye, J.-L. A. et al. Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trial. Malar. J. 10, 237 (2011). [Google Scholar]
Sagara, I. et al. A randomized trial of artesunate-sulfamethoxypyrazine-pyrimethamine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali. Am. J. Trop. Med. Hyg. 75, 630–636 2006. [Google Scholar]
Ministère de la santé, Programme National de Lutte contre le Paludisme & Pharmacie populaire du Mali. Plan de gestion des achats et des stocks. 9 (2010). [Google Scholar]
Talisuna, A. O., Staedke, S. G. & D’Alessandro, U. Pharmacovigilance of antimalarial treatment in Africa: is it possible? Malar. J. 5, 50 (2006). [Google Scholar]
Likwela, J. L. et al. Facteurs d’adhésion au traitement recommandé pour le paludisme simple au Nord-Est de la République Démocratique du Congo. Sante Publique (Bucur.) Vol. 24, 33–46 (2012). [Google Scholar]
Organisation Mondiale de la Santé. Administration de masse de médicaments contre le paludisme à falciparum : Manuel pratique. (2020). [Google Scholar]
Souares, A., Lalou, R., Sene, I., Sow, D. & Hesran, J.-Y. L. Connaissances et pratiques des agents de santé de la région de Thiès concernant la nouvelle thérapie des accès palustres. Sante Publique (Bucur.) Vol. 18, 299–310 (2006). [Google Scholar]
Ministère de la santé et de l’hygiène publique-Mali. Annuaire statistique sante. (2016). [Google Scholar]
Liu, J. et al. Factors that affect adverse drug reaction reporting among hospital pharmacists in Western China. Int. J. Clin. Pharm. 37, 457–464 2015. [Google Scholar]
Abu Hammour, K., El-Dahiyat, F. & Abu Farha, R. Health care professionals knowledge and perception of pharmacovigilance in a tertiary care teaching hospital in Amman, Jordan. J. Eval. Clin. Pract. 23, 608–613 2017. [Google Scholar]
Seid, M. A., Kasahun, A. E., Mante, B. M. & Gebremariam, S. N. Healthcare professionals’ knowledge, attitude and practice towards adverse drug reaction (ADR) reporting at the health center level in Ethiopia. Int. J. Clin. Pharm. 40, 895–902 2018. [Google Scholar]
Santosh, K. C., Tragulpiankit, P., Edwards, I. R. & Gorsanan, S. Knowledge about adverse drug reactions reporting among healthcare professionals in Nepal. Int. J. Risk Saf. Med. 25, 1–16 2013. [Google Scholar]
Afifi, S. et al. Adverse drug reactions reporting: pharmacists’ knowledge, attitude and practice in Shiraz, Iran. Int. J. Risk Saf. Med. 26, 139–145 2014. [Google Scholar]
Gurmesa, L. T. & Dedefo, M. G. Factors Affecting Adverse Drug Reaction Reporting of Healthcare Professionals and Their Knowledge, Attitude, and Practice towards ADR Reporting in Nekemte Town, West Ethiopia. BioMed Res. Int. 2016, 5728462 (2016). [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.

[1] World Health Organization & Global Malaria Programme. Global technical strategy for malaria, 2016-2030. (2015). [Google Scholar]

[2] World Health Organization. World malaria report 2020. (2021). [Google Scholar]

[3] Fougere, É. & Buxeraud, J. Les médicaments antipaludiques. Actual. Pharm. 57, 30–35 2018. [Google Scholar]

[4] Organisation Mondiale de la Santé. La prise en charge du paludisme grave : Guide Pratique. (2013). [Google Scholar]

[5] World Health Organization. Guidelines for the treatment of malaria. (2015). [Google Scholar]

[6] Assefa, D. G. et al. Efficacy and safety of dihydroartemisinin-piperaquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Ugandan children: a systematic review and meta-analysis of randomized control trials. Malar. J. 20, 174 (2021). [Google Scholar]

[7] Nji, A. M. et al. Randomized non-inferiority and safety trial of dihydroartemisin-piperaquine and artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroonian children. Malar. J. 14, 27 (2015). [Google Scholar]

[8] Ndiaye, J. L. et al. Randomized, multicentre assessment of the efficacy and safety of ASAQ--a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria. Malar. J. 8, 125 (2009). [Google Scholar]

[9] Ndiaye, J.-L. A. et al. Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trial. Malar. J. 10, 237 (2011). [Google Scholar]

[10] Sagara, I. et al. A randomized trial of artesunate-sulfamethoxypyrazine-pyrimethamine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali. Am. J. Trop. Med. Hyg. 75, 630–636 2006. [Google Scholar]

[11] Ministère de la santé, Programme National de Lutte contre le Paludisme & Pharmacie populaire du Mali. Plan de gestion des achats et des stocks. 9 (2010). [Google Scholar]

[12] Talisuna, A. O., Staedke, S. G. & D’Alessandro, U. Pharmacovigilance of antimalarial treatment in Africa: is it possible? Malar. J. 5, 50 (2006). [Google Scholar]

[13] Likwela, J. L. et al. Facteurs d’adhésion au traitement recommandé pour le paludisme simple au Nord-Est de la République Démocratique du Congo. Sante Publique (Bucur.) Vol. 24, 33–46 (2012). [Google Scholar]

[14] Organisation Mondiale de la Santé. Administration de masse de médicaments contre le paludisme à falciparum : Manuel pratique. (2020). [Google Scholar]

[15] Souares, A., Lalou, R., Sene, I., Sow, D. & Hesran, J.-Y. L. Connaissances et pratiques des agents de santé de la région de Thiès concernant la nouvelle thérapie des accès palustres. Sante Publique (Bucur.) Vol. 18, 299–310 (2006). [Google Scholar]

[16] Ministère de la santé et de l’hygiène publique-Mali. Annuaire statistique sante. (2016). [Google Scholar]

[17] Liu, J. et al. Factors that affect adverse drug reaction reporting among hospital pharmacists in Western China. Int. J. Clin. Pharm. 37, 457–464 2015. [Google Scholar]

[18] Abu Hammour, K., El-Dahiyat, F. & Abu Farha, R. Health care professionals knowledge and perception of pharmacovigilance in a tertiary care teaching hospital in Amman, Jordan. J. Eval. Clin. Pract. 23, 608–613 2017. [Google Scholar]

[19] Seid, M. A., Kasahun, A. E., Mante, B. M. & Gebremariam, S. N. Healthcare professionals’ knowledge, attitude and practice towards adverse drug reaction (ADR) reporting at the health center level in Ethiopia. Int. J. Clin. Pharm. 40, 895–902 2018. [Google Scholar]

[20] Santosh, K. C., Tragulpiankit, P., Edwards, I. R. & Gorsanan, S. Knowledge about adverse drug reactions reporting among healthcare professionals in Nepal. Int. J. Risk Saf. Med. 25, 1–16 2013. [Google Scholar]

[21] Afifi, S. et al. Adverse drug reactions reporting: pharmacists’ knowledge, attitude and practice in Shiraz, Iran. Int. J. Risk Saf. Med. 26, 139–145 2014. [Google Scholar]

[22] Gurmesa, L. T. & Dedefo, M. G. Factors Affecting Adverse Drug Reaction Reporting of Healthcare Professionals and Their Knowledge, Attitude, and Practice towards ADR Reporting in Nekemte Town, West Ethiopia. BioMed Res. Int. 2016, 5728462 (2016). [Google Scholar]